|
CMV reactivation
|
3/17 (17.6%); 3/6 of CMV IgG positive (50.0%)
|
1
|
Valganciclovir
|
8 (prophylactic)
|
|
1
|
Valganciclovir
|
8 (prophylactic)
|
|
1
|
Ganciclovir
|
5
|
|
EBV reactivation
|
1/17 (5.9%)
|
2
|
Rituximab 2 × 1 g
|
2
|
|
Mycosis
|
3/17 (17.6%)
| | | |
|
Nodular pneumonia
|
1
|
Voriconazole
|
5
|
|
Oral candidiasis
|
9
|
Nystatin
|
12 (prophylactic)
|
|
Esophageal candidiasis
|
6
|
Fluconazole
|
2
|
|
Upper respiratory tract infection
|
3/17 (17.6%)
|
9
|
Non
|
na
|
|
1
|
Azithromycin
|
24 (prophylactic)
|
|
10
|
Amoxicillin/clavulanic acid
|
1
|
|
Atypical pneumonia
|
1/17 (5.6%)
|
3
|
Piperacillin/tazobactam + linezolid
|
2
|
|
Pyelonephritis (Escherichia coli)
|
1/17 (5.9%)
|
11
|
Ciprofloxacin
|
1
|
|
Superinfected pancreatic pseudocyst (Streptococcus anginosus + Enterococcus faecalis and cloacae + Klebsiella pneumoniae)
|
1/17 (5.9%)
|
3
|
Ceftriaxone + metronidazole, meropenem, ciprofloxacin; drainage, piperacillin/tazobactam, linezolid
|
14
|
|
Lethal pneumonia with lactate acidosis
|
1/17 (5.9%)
|
9
|
Piperacillin/tazobactam
|
1
|
